Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Care | Research article

Geographical disparities in treatment and health care costs for end-of-life cancer patients in China: a retrospective study

Authors: Anli Leng, Jun Jing, Stephen Nicholas, Jian Wang

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Cancer imposes substantial burdens on cancer suffers, their families and the health system, especially in the end of life (EOL) of care patients. There are few developing country studies of EOL health care costs and no specialist studies of the disparities in cancer treatment and care costs by geographical location in China. We sought to examine geographical disparities in the types of cancer treatments and care costs during the last 3 months of life for Chinese cancer patients.

Methods

Using snowball sampling and face-to-face interviews, field research was conducted with a specialist questionnaire. Data were collected on 792 cancer patients who died between July 2013 and June 2016 in China. Total EOL health care costs were modeled using generalized linear models (GLMs) with log link and gamma distribution.

Results

Total health care costs were highest for urban (US$12,501) and western region (US$9808) patients and lowest for rural (US$5996) and central region (US$5814) patients. Our study revealed about 40% of the health care expenses occur in the last three months of life, and was mainly driven by hospital costs that accounted for about 70% of EOL expenditures. Patients faced out-of-pocket expenses for health care, with the ability to borrow from family and friends also impacting the type of treatment and health facility. Life-extending treatments per cancer patient was about two times that of patients receiving conservative treatments.Urban patients were more likely to receive life-extending treatments, financed by higher incomes and a greater capacity to borrow from family and friends to bridge the gap between health insurance reimbursements and out-of-pocket expenditures. Cancer patients in western region and urban area were significantly more likely to access hospice care.

Conclusions

We found significant urban-rural and regional disparities in EOL types of cancer treatment, utilization of medical care and the health care expenditures. The EOL cancer care costs imposed heavy economic burdens in China.We recommend better clinical guidelines, improved EOL conversations and fuller information on treatment regimes among patients, family caregivers and doctors. Policies and information should pay more attention to palliative care options and the socio-cultural context of cancer care decision-making by family.
Appendix
Available only for authorised users
Literature
4.
go back to reference Chen W, Zheng R, Baade PD, et al. Cancer statistics in China,2015. Ca A Cancer Journal for Clinicians. 2016;66(2):115–32.CrossRef Chen W, Zheng R, Baade PD, et al. Cancer statistics in China,2015. Ca A Cancer Journal for Clinicians. 2016;66(2):115–32.CrossRef
5.
go back to reference American Cancer Society. Cancer facts and figures 2008. Atlanta: American Cancer Society; 2013. American Cancer Society. Cancer facts and figures 2008. Atlanta: American Cancer Society; 2013.
6.
go back to reference Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–28.CrossRef Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–28.CrossRef
7.
go back to reference Laudicella M, Walsh B, Burns E, Smith PC. Cost of care for cancer patients in England: evidence from population-based patient-level data. Br J Cancer. 2016;114(11):1286–9.CrossRef Laudicella M, Walsh B, Burns E, Smith PC. Cost of care for cancer patients in England: evidence from population-based patient-level data. Br J Cancer. 2016;114(11):1286–9.CrossRef
8.
go back to reference Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a populationbased cost analysis. Lancet Oncol 2013; 14(12): 1165–74. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a populationbased cost analysis. Lancet Oncol 2013; 14(12): 1165–74.
9.
go back to reference Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100(9):630–41.CrossRef Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100(9):630–41.CrossRef
10.
go back to reference Langton JM, Srasuebkul P, Reeve R, et al. Resource use, costs and quality of end-of-life care: observations in a cohort of elderly Australian cancer decedents. Implement Sci. 2015;10(1):1–14.CrossRef Langton JM, Srasuebkul P, Reeve R, et al. Resource use, costs and quality of end-of-life care: observations in a cohort of elderly Australian cancer decedents. Implement Sci. 2015;10(1):1–14.CrossRef
13.
go back to reference Tangka FK, Subramanian S, Sabatino SA, et al. End-of-life medical costs of Medicaid Cancer patients. Health Serv Res. 2015;50(3):690–709.CrossRef Tangka FK, Subramanian S, Sabatino SA, et al. End-of-life medical costs of Medicaid Cancer patients. Health Serv Res. 2015;50(3):690–709.CrossRef
14.
go back to reference Wang H, Qiu F, Boilesen E, et al. Rural-urban differences in costs of end-of-life care for elderly cancer patients in the United States. J Rural Health. 2016;32(4):353–62.CrossRef Wang H, Qiu F, Boilesen E, et al. Rural-urban differences in costs of end-of-life care for elderly cancer patients in the United States. J Rural Health. 2016;32(4):353–62.CrossRef
15.
go back to reference Du XL, Parikh RC, Lairson DR. Racial and geographic disparities in the patterns of care and costs at the end of life for patients with lung cancer in 2007-2010 after the 2006 introduction of bevacizumab. Lung Cancer. 2015;90(3):442–50.CrossRef Du XL, Parikh RC, Lairson DR. Racial and geographic disparities in the patterns of care and costs at the end of life for patients with lung cancer in 2007-2010 after the 2006 introduction of bevacizumab. Lung Cancer. 2015;90(3):442–50.CrossRef
16.
go back to reference Bremner KE, Krahn MD, Warren JL, et al. An international comparison of costs of end-of-life care for advanced lung cancer patients using health administrative data. Palliat Med. 2015;29(10):918–28.CrossRef Bremner KE, Krahn MD, Warren JL, et al. An international comparison of costs of end-of-life care for advanced lung cancer patients using health administrative data. Palliat Med. 2015;29(10):918–28.CrossRef
17.
go back to reference Tan TS, Jatoi A. End-of-life hospital costs in Cancer patients: do advance directives or routes of hospital admission make a difference? Oncology. 2011;80(1–2):118–22.CrossRef Tan TS, Jatoi A. End-of-life hospital costs in Cancer patients: do advance directives or routes of hospital admission make a difference? Oncology. 2011;80(1–2):118–22.CrossRef
18.
go back to reference Morden NE, Chang CH, Jacobson JO, et al. End-of-life care for Medicare beneficiaries with cancer is highly intensive overall and varies widely. Health Aff. 2012;31(4):786–96.CrossRef Morden NE, Chang CH, Jacobson JO, et al. End-of-life care for Medicare beneficiaries with cancer is highly intensive overall and varies widely. Health Aff. 2012;31(4):786–96.CrossRef
19.
go back to reference Walsh B, Laudicella M. Disparities in Cancer care and costs at the end of life: evidence from England's National Health Service. Health Aff. 2017;36(7):1218.CrossRef Walsh B, Laudicella M. Disparities in Cancer care and costs at the end of life: evidence from England's National Health Service. Health Aff. 2017;36(7):1218.CrossRef
20.
go back to reference Thorn JC, Turner EL, Hounsome L, et al. Validating the use of hospital episode statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the cluster randomised trial of PSA testing for prostate cancer (CAP). BMJ Open. 2016;6(4):e011063.CrossRef Thorn JC, Turner EL, Hounsome L, et al. Validating the use of hospital episode statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the cluster randomised trial of PSA testing for prostate cancer (CAP). BMJ Open. 2016;6(4):e011063.CrossRef
21.
go back to reference Round J, Jones L, Morris S. Estimating the cost of caring for people with cancer at the end of life: a modelling study. Palliat Med. 2015;29(10):899.CrossRef Round J, Jones L, Morris S. Estimating the cost of caring for people with cancer at the end of life: a modelling study. Palliat Med. 2015;29(10):899.CrossRef
22.
go back to reference Balboni T, Balboni M, Paulk ME, et al. Support of cancer patients' spiritual needs and associations with medical care costs at the end of life. Cancer. 2011;117(23):5383.CrossRef Balboni T, Balboni M, Paulk ME, et al. Support of cancer patients' spiritual needs and associations with medical care costs at the end of life. Cancer. 2011;117(23):5383.CrossRef
23.
go back to reference Gomes B, Mccrone P, Hall S, et al. Variations in the quality and costs of end-of-life care, preferences and palliative outcomes for cancer patients by place of death: the QUALYCARE study. BMC Cancer. 2010;10(1):1–10.CrossRef Gomes B, Mccrone P, Hall S, et al. Variations in the quality and costs of end-of-life care, preferences and palliative outcomes for cancer patients by place of death: the QUALYCARE study. BMC Cancer. 2010;10(1):1–10.CrossRef
24.
go back to reference Reeve R, Srasuebkul P, Langton JM, et al. Health care use and costs at the end of life: a comparison of elderly Australian decedents with and without a cancer history. BMC Palliative Care. 2018;17(1):1.CrossRef Reeve R, Srasuebkul P, Langton JM, et al. Health care use and costs at the end of life: a comparison of elderly Australian decedents with and without a cancer history. BMC Palliative Care. 2018;17(1):1.CrossRef
25.
go back to reference Walker H, Anderson M, Farahati F, et al. Resource use and costs of end-of-life/palliative care: Ontario adult cancer patients dying during 2002 and 2003. J Palliat Care. 2011;27(2):79–88.CrossRef Walker H, Anderson M, Farahati F, et al. Resource use and costs of end-of-life/palliative care: Ontario adult cancer patients dying during 2002 and 2003. J Palliat Care. 2011;27(2):79–88.CrossRef
26.
go back to reference Chang HT, Lin MH, Chen CK, et al. Medical care utilization and costs on end-of-life cancer patients: the role of hospice care. Medicine. 2016;95(44):e5216.CrossRef Chang HT, Lin MH, Chen CK, et al. Medical care utilization and costs on end-of-life cancer patients: the role of hospice care. Medicine. 2016;95(44):e5216.CrossRef
27.
go back to reference Kovacević A, Dragojević-Simić V, Rancić N, et al. End-of-life costs of medical care for advanced stage cancer patients. Vojnosanit Pregl. 2015;72(4):334.CrossRef Kovacević A, Dragojević-Simić V, Rancić N, et al. End-of-life costs of medical care for advanced stage cancer patients. Vojnosanit Pregl. 2015;72(4):334.CrossRef
28.
go back to reference Langton JM, Blanch B, Drew AK, et al. Retrospective studies of end-of-life resource utilization and costs in cancer care using health administrative data: a systematic review. Palliat Med. 2014;28(10):1167–96.CrossRef Langton JM, Blanch B, Drew AK, et al. Retrospective studies of end-of-life resource utilization and costs in cancer care using health administrative data: a systematic review. Palliat Med. 2014;28(10):1167–96.CrossRef
29.
go back to reference Chiang JK, Kao YH. Predictors of high healthcare costs in elderly patients with liver cancer in end-of-life: a longitudinal population-based study. BMC Cancer. 2017;17(1):568.CrossRef Chiang JK, Kao YH. Predictors of high healthcare costs in elderly patients with liver cancer in end-of-life: a longitudinal population-based study. BMC Cancer. 2017;17(1):568.CrossRef
30.
go back to reference Feng J, Yu YY, Lou YP. Medical demand and the growth of medical costs in China-based on the difference between urban and rural elderly medical expenses. Soc Sci China. 2015;3:85–103 (in Chinese). Feng J, Yu YY, Lou YP. Medical demand and the growth of medical costs in China-based on the difference between urban and rural elderly medical expenses. Soc Sci China. 2015;3:85–103 (in Chinese).
33.
go back to reference Chen H, Zhou LL. Structural analysis of inequality of public health in China. Chin J Popul Science. 2011;6:72–83 (in Chinese). Chen H, Zhou LL. Structural analysis of inequality of public health in China. Chin J Popul Science. 2011;6:72–83 (in Chinese).
34.
go back to reference Zheng WS, Jiang HX, Ai HR, et al. Regional differences in the supply of basic health resources in China. Geogr Res. 2015;34(11):2049–60 (in Chinese). Zheng WS, Jiang HX, Ai HR, et al. Regional differences in the supply of basic health resources in China. Geogr Res. 2015;34(11):2049–60 (in Chinese).
35.
go back to reference Yu C. Evaluation of medical service level in different regions in China based on the method of factor analysis and cluster analysis. Econ Vision. 2011;12:48–52 (in Chinese). Yu C. Evaluation of medical service level in different regions in China based on the method of factor analysis and cluster analysis. Econ Vision. 2011;12:48–52 (in Chinese).
36.
go back to reference Zhao Y. Comprehensive evaluation of rural basic medical service level of each province in China based on the method of factor analysis. Public Financ Res. 2013;4:28–33 (in Chinese). Zhao Y. Comprehensive evaluation of rural basic medical service level of each province in China based on the method of factor analysis. Public Financ Res. 2013;4:28–33 (in Chinese).
37.
go back to reference Sieluk J, Goto D, Hanna N, et al. PHS118-definition of end-of-life period and quality benchmarks in terminal Cancer care: a literature review. Value Health. 2015;18(3):A267.CrossRef Sieluk J, Goto D, Hanna N, et al. PHS118-definition of end-of-life period and quality benchmarks in terminal Cancer care: a literature review. Value Health. 2015;18(3):A267.CrossRef
38.
go back to reference Biernacki P, Waldorf D. Snowball sampling: problems and techniques of chain referral sampling. Sociol Methods Res. 1981;10:141–63.CrossRef Biernacki P, Waldorf D. Snowball sampling: problems and techniques of chain referral sampling. Sociol Methods Res. 1981;10:141–63.CrossRef
39.
go back to reference Georgia RS, Hau-Chen L, Rod SH, Judith F. Recruitment of hard-to-reach population subgroups via adaptations of the snowball sampling strategy. Nurs Health Sci. 2010;12(3):369–74.CrossRef Georgia RS, Hau-Chen L, Rod SH, Judith F. Recruitment of hard-to-reach population subgroups via adaptations of the snowball sampling strategy. Nurs Health Sci. 2010;12(3):369–74.CrossRef
40.
go back to reference Gyarmathy VA, Johnston LG, Caplinskiene I, et al. A simulative comparison of respondent driven sampling with incentivized snowball sampling--the “strudel effect”. Drug Alcohol Depend. 2014;135(1):71–7.CrossRef Gyarmathy VA, Johnston LG, Caplinskiene I, et al. A simulative comparison of respondent driven sampling with incentivized snowball sampling--the “strudel effect”. Drug Alcohol Depend. 2014;135(1):71–7.CrossRef
41.
go back to reference Zeng Q, Cui FF, Yu CH, et al. Analysis of cancer incidence and mortality in China, Chin J Health Statistics, 2016,33(2):321–323.(in Chinese). Zeng Q, Cui FF, Yu CH, et al. Analysis of cancer incidence and mortality in China, Chin J Health Statistics, 2016,33(2):321–323.(in Chinese).
42.
go back to reference Arnold RG, Kotsanos JG. Panel 3: methodological issues in conducting pharmacoeconomic evaluations-retrospective and claims database studies. Value Health. 1999;2(2):82.CrossRef Arnold RG, Kotsanos JG. Panel 3: methodological issues in conducting pharmacoeconomic evaluations-retrospective and claims database studies. Value Health. 1999;2(2):82.CrossRef
43.
go back to reference Blough DK, Ramsey SD. Using Generalized Linear Models to Assess Medical Care Costs. Health Serv Outcome Res Methodol. 2000;1(2):185–202.CrossRef Blough DK, Ramsey SD. Using Generalized Linear Models to Assess Medical Care Costs. Health Serv Outcome Res Methodol. 2000;1(2):185–202.CrossRef
44.
go back to reference Zhang B, Wright AA, Huskamp HA, Nilsson ME, Maciejewski ML, et al. Health care costs in the last week of life: associations with end-of-life conversations. Arch Intern Med. 2009;169(5):480–8.CrossRef Zhang B, Wright AA, Huskamp HA, Nilsson ME, Maciejewski ML, et al. Health care costs in the last week of life: associations with end-of-life conversations. Arch Intern Med. 2009;169(5):480–8.CrossRef
45.
go back to reference Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J Med. 2011;364(21):2060–5.CrossRef Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J Med. 2011;364(21):2060–5.CrossRef
46.
go back to reference Ma MN. Comparative study on happiness index of three regions in China. Nanchang university 2015. (in Chinese). Ma MN. Comparative study on happiness index of three regions in China. Nanchang university 2015. (in Chinese).
47.
go back to reference Meng YW. Study on the non-equalization of social security expenditure in three major regions of China. Yunnan university 2014. (in Chinese). Meng YW. Study on the non-equalization of social security expenditure in three major regions of China. Yunnan university 2014. (in Chinese).
48.
go back to reference Zhou T. Analysis on the influence factors of end-of-life care decisions based on logit model. Beijing University of Traditional Chinese Medicine 2013. (in Chinese). Zhou T. Analysis on the influence factors of end-of-life care decisions based on logit model. Beijing University of Traditional Chinese Medicine 2013. (in Chinese).
49.
go back to reference Elkin EB, Bach PB. Cancer's next frontier: addressing high and increasing costs. JAMA. 2010;303(11):1086–7.CrossRef Elkin EB, Bach PB. Cancer's next frontier: addressing high and increasing costs. JAMA. 2010;303(11):1086–7.CrossRef
50.
go back to reference Meng Q,Xu L. Monitoring and evaluating age in China [serial online].PLoS Med.2014;11:e1001694.: 630–41. Meng Q,Xu L. Monitoring and evaluating age in China [serial online].PLoS Med.2014;11:e1001694.: 630–41.
51.
go back to reference Warren JL, Barbera L, Bremner KE, et al. End-of-life care for lung cancer patients in the United States and Ontario. J Natl Cancer Inst. 2011;103(11):853–62.CrossRef Warren JL, Barbera L, Bremner KE, et al. End-of-life care for lung cancer patients in the United States and Ontario. J Natl Cancer Inst. 2011;103(11):853–62.CrossRef
52.
go back to reference Nayar P, Qiu F, Watanabegalloway S, et al. Disparities in end of life care for elderly lung cancer patients. J Community Health. 2014;39(5):1012–9.CrossRef Nayar P, Qiu F, Watanabegalloway S, et al. Disparities in end of life care for elderly lung cancer patients. J Community Health. 2014;39(5):1012–9.CrossRef
53.
go back to reference Fu CB, Wang BB, Thoughts on accelerating the development of hospice Care in China, Social Governance Review, 2017(8). (in Chinese). Fu CB, Wang BB, Thoughts on accelerating the development of hospice Care in China, Social Governance Review, 2017(8). (in Chinese).
55.
go back to reference RDPAC. Responding to the Cancer Challenge with Drug Innovation.China Hospital CEO, 2017(4). (in Chinese). RDPAC. Responding to the Cancer Challenge with Drug Innovation.China Hospital CEO, 2017(4). (in Chinese).
56.
go back to reference Magnani R, Sabin K, Saidel T, Heckathorn D. Review of sampling hard-to-reach and hidden populations for HIV surveillance. AIDS. 2005;19(Suppl. 2):67–72.CrossRef Magnani R, Sabin K, Saidel T, Heckathorn D. Review of sampling hard-to-reach and hidden populations for HIV surveillance. AIDS. 2005;19(Suppl. 2):67–72.CrossRef
57.
go back to reference Hilber AM, Hull TH, Preston-Whyte E , et al. A cross cultural study of vaginal practices and sexuality: implications for sexual health. Soc Sci Med, 2010, 70(3):392–400. Hilber AM, Hull TH, Preston-Whyte E , et al. A cross cultural study of vaginal practices and sexuality: implications for sexual health. Soc Sci Med, 2010, 70(3):392–400.
58.
go back to reference Meter KMV. Methodological and Design issues: techniques for assessing the representatives of snowball samples. NIDA Res Monogr, 1990, 98(98):31. Meter KMV. Methodological and Design issues: techniques for assessing the representatives of snowball samples. NIDA Res Monogr, 1990, 98(98):31.
59.
go back to reference Kaplan CD, Korf D, Sterk C. Temporal and social contexts of heroin-using populations. An illustration of the snowball sampling technique. J Nerv Ment Dis. 1987;175(9):566–74.CrossRef Kaplan CD, Korf D, Sterk C. Temporal and social contexts of heroin-using populations. An illustration of the snowball sampling technique. J Nerv Ment Dis. 1987;175(9):566–74.CrossRef
Metadata
Title
Geographical disparities in treatment and health care costs for end-of-life cancer patients in China: a retrospective study
Authors
Anli Leng
Jun Jing
Stephen Nicholas
Jian Wang
Publication date
01-12-2019
Publisher
BioMed Central
Keyword
Care
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-5237-1

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine